StocksMedium•16 November 2026•
1 min read
ALX Oncology Reports Narrower-Than-Expected Q3 2026 Loss
Key Facts
1ALX Oncology reported an adjusted loss per share of $0.13, beating the consensus estimate of a $0.14 loss.
2The company's losses narrowed by 63.89% year-over-year compared to the $0.36 loss per share recorded in the same period last year.
3The company ended the third quarter with cash, cash equivalents, and investments totaling $147.2 million.
ALX Oncology reported an adjusted loss per share of $0.13 for the third quarter of 2026, beating the consensus estimate of a $0.14 loss. According to scanx.trade, the company's losses narrowed by 63.89% year-over-year compared to the $0.36 loss per share recorded in the same period last year. The company ended the quarter with cash, cash equivalents, and investments totaling $147.2 million.
ALXO closed at $1.04 on November 13, 2026, with the stock trading between a day low of $0.9361 and a high of $1.12 during that session. These financial results reflect an improvement in operational efficiency as the company maintains its research and development activities supported by a solid cash position.